IRON at a glance
Disc Medicine, Inc. (IRON, SEC CIK 1816736) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on September 10, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Disc Medicine, Inc. (IRON) shares worth $1.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Bitterman Kevin on September 11, 2026 of 27,136 shares at $70.11 per share.
- In the last 90 days, IRON insiders reported 0 open-market purchases ($0) and 26 open-market sales ($12.7M) on Form 4, a net sale of $12.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 26 sells
- Net −$12.7M
- 13F holders
- 27 funds
- $1.2B · +1 vs prior quarter
- Latest 8-K
- Sep 10, 2026
- Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: clinical-stage biopharma developing novel treatments targeting red blood cell biology, focusing on heme biosynthesis and iron homeostasis pathways
- New emphasis: submission of NDA for bitopertin in erythropoietic porphyrias (EPP and XLP) with FDA accelerated approval pursuit, ongoing Phase 3 APOLLO trial initiated May 2025
- Strategic shift: pivot to address FDA complete response letter by generating Phase 3 data for traditional approval; expanding pipeline into myeloproliferative neoplasms with DISC-0974 and DISC-3405
- Quantitative highlight: approx. 14,000 diagnosed EPP patients US market; Phase 2 trial of DISC-0974 in myelofibrosis anemia showed anemia responses independent of transfusion or JAK inhibitor use
- Noteworthy fact: received FDA Commissioner’s National Priority Voucher in October 2025 for bitopertin, highlighting regulatory priority for this rare disease therapy
Risk Factors
- Regulatory risk: Dependency on FDA approval timing and conditions for product candidates impacts commercialization and cost structure
- Macroeconomic threat: Cash runway extends only to 2029 with $791.2M liquidity; accelerated spending could exhaust funds earlier
- Supply chain vulnerability: Reliance on third-party CROs and CDMOs for clinical trials and manufacturing with some non-cancellable fees
- Competitive risk: Potential market disruption from approved therapies competing with bitopertin or other pipeline products
- Financial risk: Accumulated deficit $510.2M with increasing annual net losses ($212.2M in 2025) and heavy equity reliance for funding
Management Discussion & Analysis
- No revenue generated; net loss $212.2M in 2025 vs $109.4M in 2024, loss doubled YoY
- Operating expenses up $106.3M YoY: R&D $170.6M vs $96.7M, SG&A $65.4M vs $33.0M
- R&D increase driven by bitopertin ($58.8M, +$30.7M), DISC-0974 ($27.6M, +$10.6M); bitopertin lead program
- Cash and equivalents $791.2M at end 2025; raised $211.0M net proceeds in Oct 2025 equity offering
- FDA issued CRL for bitopertin NDA in Feb 2026; APOLLO Phase 3 topline data expected Q4 2026 to support resubmission
AI summary of the IRON 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged year over year; no product sales since inception
- Operating margin not applicable; net loss $59.5M vs $55.2M YoY
- Best R&D performer: selcodebart spending $12.4M, up $7.7M YoY
- Worst R&D performer: bitopertin spending $8.7M, down $15.0M YoY
- Cash, equivalents and securities $717.7M; operating cash use $106.4M and debt proceeds $30.0M through June 30
Risk Factors
- Net losses $123.0 million for six months ended June 30, 2026, versus $89.3 million in 2025
- Cash, equivalents, and marketable securities expected to fund operations and debt service into 2029
- Hercules term loan up to $200.0 million, maturing December 1, 2029, secured by substantially all non-intellectual-property assets
- Clinical programs remain exposed to FDA demands for additional trials or stricter approval conditions
- Three product candidates in clinical development, with none having completed Phase 3 trials
AI summary of the IRON 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Initial RESTORE-PV Phase 2 results for DISC-3405 in polycythemia vera
- Press release issued September 9, 2026, with substantive trial data in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- RESTORE-PV Phase 2 data support DISC-3405’s mechanism, linking higher hepcidin and lower serum iron to hematocrit control
- Mean phlebotomies fell from 4.0 to 0.6 over 26 weeks among 13 Cohort A completers, with p<0.0001
Item 8.01: Other Events
- Phase 2 RESTORE-PV enrolled 40 adults; Cohort A dosing every 2 weeks, Cohort B every 4 weeks
- Cohort A mean hematocrit stayed below 45% through week 26, with initial symptom-burden improvement
Item EX-99.1: Item EX-99.1
- Q2 net loss $59.5M versus $55.2M; six-month loss widened to $123.0M versus $89.3M
- Cash, equivalents, and marketable securities $717.7M, funding operations into 2029 without near-term financing pressure
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Corporate update accompanied the financial results announcement
Item 1.01: Entry into a Material Definitive Agreement
- No substantive Item 1.01 agreement terms provided in the excerpt
- Filing signed June 30, 2026 by John Quisel, President and Chief Executive Officer
AI summaries of IRON 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IRON
Don't miss the next IRON filing
- Alerts as it files. A push when IRON files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IRON, by share count.
- Ask anything. An AI agent that reads every IRON filing and answers with sources.
IRON alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Quisel John D | M | Sep 15, 2026 | 36,000 | - |
| Quisel John D | M | Sep 15, 2026 | 36,000 | $1.01 |
| Bitterman Kevin | M | Sep 11, 2026 | 10,000 | - |
| Bitterman Kevin | M | Sep 11, 2026 | 10,000 | $38.85 |
| Bitterman Kevin | Sell | Sep 11, 2026 | 27,136 | $70.11 |
| Bitterman Kevin | M | Sep 11, 2026 | 7,136 | - |
| Bitterman Kevin | M | Sep 11, 2026 | 10,000 | $50.86 |
| Bitterman Kevin | M | Sep 11, 2026 | 7,136 | $45.69 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$91.1M | -$129.7M | -$236.0M |
| Net Income | -$76.4M | -$109.4M | -$212.2M |
| Balance Sheet | |||
| Total Assets | $368.0M | $496.8M | $806.9M |
| Equity | - | $443.6M | $739.8M |
| ROE | - | -24.7% | -28.7% |
| Per Share | |||
| EPS | $-3.42 | $-3.96 | $-6.01 |
| Cash Flow | |||
| Operating CF | -$73.5M | -$93.9M | -$180.4M |
| CapEx | $89K | $505K | $933K |
Source: XBRL data in Disc Medicine, Inc. (IRON)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate IRON share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $1.21B |
| Q1 2026 | 26 | $1.03B |
| Q4 2025 | 23 | $1.28B |
| Q3 2025 | 24 | $931.5M |
| Q2 2025 | 23 | $604.9M |
| Q1 2025 | 20 | $385.7M |
| Q4 2024 | 16 | $318.1M |
| Q3 2024 | 9 | $76.8M |
- JPMorgan Chase & Co+504.3K (+37%)
- T. Rowe Price Group+326.0K (+21%)
- BlackRock+194.1K (+9%)
- Dimensional Fund Advisors+174.6K (+44%)
- Citadel Advisors LLC+111.4K (+114%)
- FMR LLC (Fidelity)−692.4K (-12%)
- Goldman Sachs Group−542.5K (-85%)
- State Street Corp−49.4K (-3%)
- Bank of America Corp−31.7K (-19%)
- Vanguard Capital Management LLC−6.4K (-0%)
- Two Sigma Investments+136.8K
- D.E. Shaw & Co+6.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 168 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IRON filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
IRON SEC filings: frequently asked questions
Are IRON insiders buying or selling?
In the last 90 days, Disc Medicine, Inc. (IRON) officers, directors and 10% owners reported no open-market purchases and 26 open-market sales worth $12.7 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold IRON stock?
As of June 30, 2026, the largest Disc Medicine, Inc. (IRON) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($358.0 million), BlackRock ($180.5 million), JPMorgan Chase & Co ($139.9 million), T. Rowe Price Group ($137.2 million), State Street Corp ($120.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in IRON's latest 10-K?
In the 10-K filed February 26, 2026, Disc Medicine, Inc. (IRON) flagged: Regulatory risk: Dependency on FDA approval timing and conditions for product candidates impacts commercialization and cost structure. Macroeconomic threat: Cash runway extends only to 2029 with $791.2M liquidity; accelerated spending could exhaust funds earlier. (AI summary of the Risk Factors section.)
What did IRON report in its latest 8-K?
Disc Medicine, Inc. (IRON) filed an 8-K on September 10, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Initial RESTORE-PV Phase 2 results for DISC-3405 in polycythemia vera.
What are the latest IRON SEC filings?
Disc Medicine, Inc. (IRON) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 30, 2026, an 8-K current report on September 10, 2026 and a Form 4 insider filing on September 16, 2026.
What is IRON's SEC CIK number?
Disc Medicine, Inc. (IRON)'s SEC Central Index Key (CIK) is 1816736. EDGAR lists every IRON filing under that number.
Ask anything about IRON
The research agent reads IRON's filings, financials, insider trades and 13F holders, then answers with sources.